

## SUPPLEMENTARY MATERIAL

*Communication*

# Resveratrol-Schiff base hybrid compounds with selective antibacterial activity: Synthesis, biological activity, and computational study

Rodrigo Sánchez-González <sup>1</sup>, Patricio Leyton <sup>1</sup>, Luis F. Aguilar <sup>1</sup>, Mauricio Reyna-Jeldes <sup>2-4</sup>, Claudio Coddou <sup>2-4</sup>, Katy Díaz <sup>5,\*</sup>, Marco Mellado <sup>6,\*</sup>

<sup>1</sup> Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso 2373223, Chile; rodrigo.sanchez.g@pucv.cl (R.S-G.); patricio.leyton@pucv.cl (P.L.)

<sup>2</sup> Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad Católica Del Norte, Coquimbo 1781421, Chile; mauricio.reyna@ucn.cl (M.R-J.); ccoddou@ucn.cl (C.C.)

<sup>3</sup> Millennium Nucleus for the Study of Pain (MiNuSPain), Santiago 8330025, Chile; mauricio.reyna@ucn.cl (M.R-J.); ccoddou@ucn.cl (C.C.)

<sup>4</sup> Núcleo para el Estudio del Cáncer a Nivel Básico, Aplicado y Clínico, Universidad Católica del Norte, Antofagasta 1270709, Chile; mauricio.reyna@ucn.cl (M.R-J.); ccoddou@ucn.cl (C.C.)

<sup>5</sup> Departamento de Química, Universidad Técnica Federico Santa María, Valparaíso 2390123, Chile; katy.diaz@usm.cl (K.D.)


<sup>6</sup> Instituto de Investigación y Postgrado, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile; marco.mellado@ucentral.cl (M.M.)

\* Correspondence: katy.diaz@usm.cl (K.D.); marco.mellado@ucentral.cl (M.M.)


## Table of Content

<u>Spectra S1-S18: FT-IR, <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra for symmetric (9a-9e) and asymmetric imines (10a)</u> .....	2
<u>Figures S1-S6: Molecular docking results</u> .....	14


**Spectra S1-S18: FT-IR,  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectra for symmetric (9a-9e) and asymmetric (10a) imines**




**Spectra S1:** FT-IR of compound 9a




**Spectra S2:**  $^1\text{H}$ -NMR of compound 9a




**Spectra S3:** <sup>13</sup>C-NMR of compound 9a




**Spectra S4:** FT-IR of compound **9b**




**Spectra S5:** <sup>1</sup>H-NMR of compound **9b**




**Spectra S6:**  $^{13}\text{C}$ -NMR of compound **9b**




**Spectra S7:** FT-IR of compound 9c




**Spectra S8:** <sup>1</sup>H-NMR of compound 9c




Spectra S9: <sup>13</sup>C-NMR of compound 9c




**Spectra S10:** FT-IR of compound 9d







**Spectra S12:**  ${}^{13}\text{C}$ -NMR of compound 9d




**Spectra S13:** FT-IR of compound **9e**




**Spectra S14:** <sup>1</sup>H-NMR of compound **9e**




**Spectra S15:** <sup>13</sup>C-NMR of compound 9e



**Spectra S16:** FT-IR of compound **10a**




**Spectra S17:** <sup>1</sup>H-NMR of compound **10a**




Spectra S18: <sup>13</sup>C-NMR of compound 10a


## Figures S1-S6: Molecular docking results




**Figure S1:** Molecular docking results for active compounds on positive regulatory factor A (PrfA, PDB ID: ILRR). **A.** 3D-overview for native ligand on the active site of PrfA. **B.** 3D-overview for active compounds on the active site of PrfA. **C.** Detailed interaction between key residues and the most active compound (**9b**).




**Figure S2:** Molecular docking results for active compounds on penicillin-binding protein 4 (PBPs4, PDB ID: 3ZG8). **A.** 3D-overview for native ligand the on active site of PBPs4. **B.** 3D-overview for active compounds the on active site of PBPs4. **C.** Detailed interaction between key residues and the most active compound (**9b**).




**Figure S3:** Molecular docking results for active compounds on internalin A (PDB ID: 1O6V).  
A. 3D-overview for native ligand on the active site of internalin A. B. 3D-overview for active compounds on the active site of internalin A. C. Detailed interactions between key residues and the most active compound (**9b**).



**Figure S4:** Molecular docking results for the active compounds against internalin B (PDB ID: 2WQU). **A.** 3D-overview for native ligand on the active site of internalin B. **B.** 3D-overview for active compounds on the active site of internalin B. **C.** Detailed interaction between key residues and the most active compound (**9b**).



**Figure S5:** Molecular docking result for active compounds against internalin C (PDB ID: 1XEU). **A.** 3D-Overview for native ligand on the active site of internalin C. **B.** 3D-overview for active compounds on the active site of internalin C. **C.** Detailed interaction between key residues and the most active compound (**9b**).



**Figure S6:** Molecular docking results for compound **9b** and **resveratrol** against internalin C (PDB ID: 1XEU). **A.** 3D-overview for compound **9b** and **resveratrol** on the active site of internalin C. **B.** Detailed interaction between key residues and compound **9b**. **C.** Detailed interaction between key residues and **resveratrol**.